Medicine and Dentistry
Adverse Event
8%
Anemia
16%
Bevacizumab
33%
Blood Sampling
16%
Blood Toxicity
8%
Cancer Cell
11%
Cervical Cancer
48%
Cervicectomy
66%
Chemotherapy
13%
Clinical Feature
33%
DNA Damage
33%
Fatality
8%
Homologous Recombination
8%
Hormone Determination
29%
Hypoxia
11%
Infusion
9%
Interleukin 33
33%
Lanatoside C
9%
Lymph Node Metastasis
33%
Lymphocyte
33%
Lymphoid Cell
8%
Maintenance Therapy
8%
Malignant Ascites
33%
Malignant Neoplasm
8%
Mean Platelet Volume
33%
Mesenchymal-Epithelial Transition
33%
Metastatic Carcinoma
11%
Minimally Invasive Procedure
33%
Nausea
8%
Niraparib
33%
Obstetrics
33%
Olaparib
33%
Ovarian Cancer
33%
Ovarian Reserve
33%
Overall Survival
20%
Paracentesis
29%
PARP Inhibitor
33%
Progression Free Survival
12%
Prospective Study
33%
Recurrent Disease
12%
Recurrent Ovarian Cancer
33%
Retrospective Cohort Study
8%
Retrospective Study
8%
Safety Assessment
33%
Serous Carcinoma
8%
Tertiary Lymphoid Structure
16%
Thrombocytopenia
16%
Treatment Interruption
8%
Uncoupling Protein 2
33%
Uterine Cancer
66%
Keyphrases
Adverse Events
6%
Anti-Mllerian Hormone
29%
Ascitic Fluid
6%
Bevacizumab
33%
Bevacizumab Therapy
26%
Blood Toxicity
8%
Cancer Center
6%
Clinical Benefit
6%
Clinical Data
6%
Controlled Ovarian Stimulation
8%
Conventional Chemotherapy
13%
DDIT4
33%
Digital Analysis
16%
DNA Damage-inducible Transcript 4
33%
Epithelial Ovarian Cancer
13%
Fertility-preserving Treatment
6%
Half-dose
13%
Heavily Pretreated
6%
Heavily Treated
33%
Hormone Levels
29%
Independent Prognostic Factor
5%
Informed Consent
6%
Interventional Study
6%
Lanatoside C
9%
Let-7 Family
33%
Lymphorrhea
6%
Malignant Ascites
33%
Mean Platelet Volume
33%
Medical Expenses
6%
Ovarian Cancer
6%
Ovarian Cancer Ascites
5%
Ovarian Clear Cell Carcinoma
33%
Ovarian Reserve
33%
Palliative Approach
13%
Paracentesis
20%
Performance Prediction
11%
Peritumoral Lymphocytes
33%
Platinum Resistance
6%
Potential Biomarkers
33%
Progressive Disease
6%
Radical Trachelectomy
33%
Random Forest Regression
11%
Recurrent Ovarian Cancer
33%
Simple Trachelectomy
6%
Small EVs
33%
Specific Treatment
6%
Survival Outcomes
33%
Tai Chi
6%
Terminal Stage
6%
Vaccinia-related Kinase
33%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
8%
Anemia
16%
Aubergine
8%
Bevacizumab
33%
Blood Toxicity
8%
Carcinoma
8%
Clinical Feature
33%
Disease
11%
Female Genital Tract Cancer
6%
Interleukin 33
33%
Lanatoside C
9%
Malignant Ascites
33%
microRNA
33%
Nanoparticle
6%
Nausea
8%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
33%
Niraparib
33%
Olaparib
33%
Ovary Cancer
100%
Recurrent Disease
8%
Retrospective Study
8%
Safety Assessment
33%
Therapeutic Effect
6%
Thrombocytopenia
16%
Vaccinia
33%
Western Blot
6%
